| 查看: 620 | 回复: 0 | |||
ienjoysun银虫 (著名写手)
|
[交流]
Takeda expands vaccine platform rights with Nanotherapeutics agreement
|
|
Takeda expands vaccine platform rights with Nanotherapeutics agreement August 27, 2015 | By Eric Sagonowsky In an effort to widen the reach of its flu vaccines business--and to develop new vaccines on a familiar platform--Takeda has inked an agreement to expand its rights to the Vero cell technology platform for vaccines production from Florida's Nanotherapeutics, Inc. Takeda will gain access to the Vero technology--which Nanotherapeutics purchased from Baxalta ($BXLT)--to commercialize its pandemic and seasonal flu vaccines for Japan and other regions and to develop vaccines beyond flu. The financial terms of the deal weren't disclosed. Takeda began using the Vero platform when it signed a deal with Baxter in 2010 to license rights for the development of pandemic and seasonal flu vaccines for the Japanese market. It's currently working with the platform on TAK-850, a cell-based seasonal flu vaccine, also for use in Japan. Late last year, as it was gearing up to split its bioscience division into Baxalta, Baxter ($BAX) announced its intentions to sell the proprietary technology to Nanotherapeutics. Date: Wednesday, September 9th | 11am ET / 8am PT With biopharma companies hitching their long-term growth plans to success in emerging markets, they can ill-afford for logistical difficulties in new territories to scuttle their ambitions. This is a real risk, though. Transporting drugs to patients in Brazil, India and China is fraught with multiple challenges for which experience of shipping products in the West offers scant preparation. Register Now! Takeda vaccines president Rajeev Venkayya Takeda's vaccines president Rajeev Venkayya said in a Thursday statement the deal creates "the opportunity to expand the reach of Takeda's pandemic and seasonal flu vaccines" and "reinforces Takeda's commitment to its global vaccine business and our goal of reaching as many people as possible with vaccines that address important unmet needs in global public health." As CEO Christophe Weber works to engineer a turnaround for Japan's oldest pharma, he has said the company will look with an increased focus on vaccines, and Takeda's recent moves demonstrate that. In February, the company placed a vaccines hub in Singapore with an infectious diseases focus as part of an effort to "accelerate the globalization" of its vaccines unit. A short time later, in June, it announced its intention to consolidate U.S. vaccines ops in Cambridge, MA, to "execute Phase III clinical programs and set the stage for commercialization" of its dengue and norovirus vaccines, Venkayya said at the time. Weber has also said the firm isn't ignoring the Indian vaccines market, with Takeda executives saying in January that the company identified several M&A targets there as potential entry points. |
回复此楼» 猜你喜欢
极限拉扯，如何抉择
已经有15人回复
-
申请科研项目纯靠实力能成功吗？
已经有8人回复
-
中科院海洋所招收海洋材料相关领域博士研究生及研究助理
已经有4人回复
-
40+中年人失业后，还能找到好工作吗？
已经有3人回复
-
二审4个多月了还是Awaiting Reviewer Scores
已经有4人回复
-
OpenAI又攻克数学难题了，离AI做有机合成还有多远？
已经有13人回复
-
课题组会帮你通过考核么？
已经有7人回复
-
入职后第一次管课题组的专利缴费，对账才发现官费比别人多掏了一倍
已经有6人回复
-
售一区SCI文章T0P，我:8O.551.O54,科目全,可十急
已经有9人回复
-
售SCI一区文章，我:8O5.5.1.O5.4,科目全,可伽急
已经有10人回复
200
